Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (DRKS00040859) titled 'Safety and Pharmacokinetics of Spermidine Supplementation in Adults with BMI = 27 kg/m²: An Ascending Dose Study' on July 21.
Study Type: interventional
Study Design:
Allocation: Randomized controlled study
Masking: Blinded (masking used)
Control: placebo
Assignment: parallel
Study design purpose: other
Primary Sponsor: Medizinische Universitat Graz
Condition:
Healthy individuals with a BMI of = 27 kg/m²
Intervention:
Group 1: CelVio Complex (Spermidine)
Appearance Powder
Dose: 12, 24,48 or 96 mg orally per day
Dose 12, 24 and 48 mg daily over a duration of 28 days
Recruitment Status: Recruiting
Ph...